Evidence map›Paper›PMID 37656413›Full record

ArticleChinese journal of integrative medicine2023

Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial.

Yu-Jie Wu, Bo Deng, Si-Bo Wang, Rui Qiao, Xi-Wen Zhang, Yuan Lu, Li Wang, Shun-Zhong Gu, Yu-Qing Zhang, Kai-Qiao Li and 6 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05000411 (The Impact of Traditional Chinese Medicine, Compound Danshen Dropping Pills), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05000411 phase4unknown statusnot on this map

The Impact of Traditional Chinese Medicine, Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling: A Multicentre, Randomized, Double-blind, Placebo-controlled, Pilot Study

TypeinterventionalSponsorThe First Affiliated Hospital with Nanjing Medical UniversityRan2021 to 2024Enrolled268ConditionsMyocardial InfarctionArmsCompound Danshen Dropping Pills (CDDP), Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 1 country.

Yu-Jie WuDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Bo DengDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Si-Bo WangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Rui QiaoDepartment of Cardiology, Anqing Municipal Hospital Affiliated to Anhui Medical University, Anqing, Jiangsu Province, 246003, China.
Xi-Wen ZhangDepartment of Cardiology, Huai'an First People's Hospital, Huai'an, Jiangsu Province, 223300, China.
Yuan LuDepartment of Cardiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, 221006, China.
Li WangDepartment of Cardiology, Pukou Branch of Jiangsu People's Hospital, Nanjing, 211899, China.
Shun-Zhong GuDepartment of Cardiology, Hai'an People's Hospital, Nantong, Jiangsu Province, 226699, China.
Yu-Qing ZhangDepartment of Cardiology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, 211199, China.
Kai-Qiao LiDepartment of Cardiology, Qixia District Hospital of Nanjing City, Nanjing, 210046, China.
Zong-Liang YuDepartment of Cardiology, the First People's Hospital of Kunshan Affiliated to Jiangsu University, Kunshan, Jiangsu Province, 215300, China.
Li-Xing WuDepartment of Cardiology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 211299, China.
Sheng-Biao ZhaoDepartment of Cardiology, Nanjing Meishan Hospital, Nanjing, 210039, China.
Shuang-Lin ZhouDepartment of Cardiology, Nanjing Meishan Hospital, Nanjing, 210039, China.
Yang YangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Lian-Sheng WangDepartment of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. drlswang@njmu.edu.cn.
Nanjing Medical University · CNJiangsu Province Hospital · CNAnhui Medical University · CNHuaian First People’s Hospital · CNJiangsu University · CNNanjing Traditional Chinese Medicine Hospital · CNSecond People's Hospital of NanTong · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVentricular remodeling after acute anterior wall ST-segment elevation myocardial infarction (AAMI) is an important factor in occurrence of heart failure which additionally results in poor prognosis. Therefore, the treatment of ventricular remodeling needs to be further optimized. Compound Danshen Dripping Pills (CDDP), a traditional Chinese medicine, exerts a protective effect on microcirculatory disturbance caused by ischemia-reperfusion injury and attenuates ventricular remodeling after myocardial infarction.

objectiveThis study is designed to evaluate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function after AAMI on a larger scale.

methodsThis study is a multi-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The total of 268 patients with AAMI after primary percutaneous coronary intervention (pPCI) will be randomly assigned 1:1 to the CDDP group (n=134) and control group (n=134) with a follow-up of 48 weeks. Both groups will be treated with standard therapy of ST-segment elevation myocardial infarction (STEMI), with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets 3 times daily after pPCI, and the control group treated with a placebo simultaneously. The primary endpoint is 48-week echocardiographic outcomes including left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVI), and left ventricular end-systolic volume index (LVESVI). The secondary endpoint includes the change in N terminal pro-B-type natriuretic peptide (NT-proBNP) level, arrhythmias, and cardiovascular events (death, cardiac arrest, or cardiopulmonary resuscitation, rehospitalization due to heart failure or angina pectoris, deterioration of cardiac function, and stroke). Investigators and patients are both blinded to the allocated treatment. DISCUSSION: This prospective study will investigate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function in patients undergoing pPCI for a first AAMI. Patients in the CDDP group will be compared with those in the control group. If certified to be effective, CDDP treatment in AAMI will probably be advised on a larger scale. (Trial registration No. NCT05000411).

Indexed as

Drugs, Chinese HerbalHeart FailureMyocardial InfarctionPercutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansMicrocirculationMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeVentricular Function, LeftVentricular RemodelingDrugs, Chinese Herbalacute anterior myocardial infarctioncardiac functionCompound Danshen Dripping Pillsrandomized controlled trialtrial designventricular remodeling

Identifiers

PMID37656413
OpenAlexW4386346586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.